THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY published 11 principles and detailed guidance to the Centers for Medicare & Medicaid Services as it implements the Merit-based Incentive Payment System and Alternative Payment Models under the Medicare Access and CHIP Reauthorization on Act of 2015, which replaced the Sustainable Growth Rate formula.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
